Brachyury peptide va…une, Inc.) Drug Due Diligence 2026

This Brachyury peptide vaccine(GlobeImmune, Inc.) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Brachyury peptide vaccine(GlobeImmune, Inc.) can convert its Personalized antigen vaccine, Therapeutic vaccine profile and TBXT biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Brachyury peptide vaccine(GlobeImmune, Inc.) (query alias: Brachyury peptide vaccine(GlobeImmune, Inc.))
Modality / target	Personalized antigen vaccine, Therapeutic vaccine; TBXT; TBXT modulators
Highest global status	Phase 2
Originator	GlobeImmune, Inc.
Active developers	National Cancer Institute, GlobeImmune, Inc.

The MCP disease footprint includes Invasive Mammary Carcinoma, Metastatic breast cancer, Metastatic Triple-Negative Breast Carcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT03647423	Phase 1/2	Withdrawn	0	Primary endpoint not disclosed in English source
NCT03606967	Phase 2	Recruiting	86	Primary endpoint not disclosed in English source
NCT03586869	Phase 1/2	Terminated	3	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

NANT Colorectal Cancer (CRC) Vaccine: A Phase 1b/2 Trial of the NANT CRC Vaccine vs Regorafenib in Subjects With Metastatic CRC Who Have Been Previously Treated With Standard-of-Care Therapy

Phase 1/2; n=2; evaluation: Not stated in English source. Reported fields: TEAE = 2 Pts ; Other (Not Including Serious) Adverse Events = 0 Pts

QUILT-3.080: Phase 1B/2 Trial Of The NANT Pancreatic Cancer Vaccine As Treatment For Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-Of-Care Therapy

Phase 1/2; n=3; evaluation: Not stated in English source. Reported fields: TEAE = 3 Pts

NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Phase 1/2; n=9; evaluation: Not stated in English source. Reported fields: TEAE = 9 Pts

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Brachyury peptide vaccine(GlobeImmune, Inc.) addresses Invasive Mammary Carcinoma, Metastatic breast cancer, Metastatic Triple-Negative Breast Carcinoma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Personalized antigen vaccine, Therapeutic vaccine—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2009-05-17	GlobeImmune and Celgene Corporation Announce Strategic Global Oncology Alliance	Phase 2	US$40.0M upfront; US$500.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods of treating cancer”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Immunogenicity durability and clinically meaningful protection
Population selection, endpoint timing, and comparator relevance
Manufacturing consistency, distribution, and uptake

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO